Trial Profile
Treatment Of inoperable carcinoma Merkel cells and / or metastatic By somatostatin analogue - National Multicenter Study Single-arm Phase II [Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms PHRC-Merkel
- 31 Aug 2017 Status changed from recruiting to completed.
- 12 Aug 2015 Planned End Date changed from 1 Feb 2018 to 1 Apr 2019 as per ClinicalTrials.gov .
- 12 Aug 2015 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2019 as per ClinicalTrials.gov .